Charged with delivering advanced therapeutics in today’s fast-paced market, as a CDMO, agility is everything. From an operational standpoint, CDMOs must have the necessary infrastructure to successfully support a wide range of products. This begins with a strong foundation of both advanced capabilities and highly trained teams. Denis Johnson, GRAM’s CEO shares insight leveraging his extensive experience in sterile fill-finish and running CDMO facilities, on anticipating trends, addressing challenges, and providing solutions, as well as flexibility that enables CDMOs to adapt to market changes.